Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study assessing PF-1801 for Duchenne muscular dystrophy

Next Previous
Trial Profile

A phase II study assessing PF-1801 for Duchenne muscular dystrophy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 1801 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors ImmunoForge

Most Recent Events

  • 14 Jan 2025 According to an Immunoforge media release, company has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' for treatment of DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration (FDA).
  • 17 Oct 2023 According to an Immunoforge media release, the company has received Phase 2 clinical trial approval from the U.S. FDA.
  • 03 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top